Hipertensión arterial pulmonar en Colombia: ciencia, estrategia y evidencia real en un entorno fragmentado

Pulmonary arterial hypertension (PAH) is a progressive and potentially life-threatening disease characterized by vascular remodeling and right ventricular dysfunction. While therapies targeting classical pathways exist, new options such as sotatercept and seralutinib show promise. However, their impact will depend on timely diagnosis and sustained treatment, which face challenges in Colombia due to structural inequities and the lack of specialized centers. The Colombian Pulmonary Hypertension Network (HAPredCO) has developed a model based on regional nodes and a central operational core that promotes research, equitable access to knowledge, and the ethical management of clinical data. Studies from the network have revealed low concordance between non-invasive diagnostic methods and hemodynamic measurements, as well as a high prevalence of malnutrition and a predominance of PAH associated with congenital heart disease. Moreover, altitude influences the clinical profile and therapeutic response, underscoring the need for risk assessment tools adapted to the local context.